Since hyperactivation of FGFR4 signaling has also been shown to confer chemoresistance in breast, gastric and colorectal cancer cells [47, 67–70], we hypothesized that the combined application of anti-FGF19 neutralizing antibody and chemotherapeutic agents might further increase the apoptosis rate of cancer cells. This evidence concerns the gene FGF19 and cancer.